Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer

Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer

Anthracyclines are among the most active chemotherapies (CT) in breast cancer (BC). However, cardiotoxicity is a risk and peculiar side effect that has been limiting their use in clinical practice, especially after the introduction of taxanes. Non-pegylated liposomal doxorubicin (NPLD) has been deve...

Full description

Bibliographic Details
Main Authors: Francesco Schettini, Mario Giuliano, Matteo Lambertini, Rupert Bartsch, David James Pinato, Concetta Elisa Onesti, Nadia Harbeck, Diana Lüftner, Sylvie Rottey, Peter A. van Dam, Khalil Zaman, Giorgio Mustacchi, Joseph Gligorov, Ahmad Awada, Mario Campone, Hans Wildiers, Alessandra Gennari, Vivianne C. G. Tjan-Heijnen, Javier Cortes, Mariavittoria Locci, Ida Paris, Lucia Del Mastro, Sabino De Placido, Miguel Martín, Guy Jerusalem, Sergio Venturini, Giuseppe Curigliano, Daniele Generali
Format: Article
Language:English
Published: MDPI AG 2021-09-01
Series:Cancers
Subjects:
anthracyclines
breast cancer
triple negative
hormone receptor
metastatic
non-pegylated liposomal doxorubicin
Online Access:https://www.mdpi.com/2072-6694/13/17/4421

Internet

https://www.mdpi.com/2072-6694/13/17/4421

Similar Items